Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China 2024-08-30 19:34
Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO 2024-06-02 08:25
Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint 2024-05-01 08:59
Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting 2024-04-09 19:59
Jacobio Pharma Announces 2023 Annual Results 2024-03-29 08:50
Jacobio Pharma Receives IND Approval for P53 Y220C Activator JAB-30300 in the U.S. 2024-03-01 14:55
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor 2024-02-18 20:50
Jacobio Pharma Presents Data of Glecirasib in Patients with Pancreatic Cancer and Other Solid Tumors at the 2024 ASCO GI 2024-01-20 06:30
Jacobio Pharma Presents Clinical Results of Glecirasib in Combination with JAB-3312 at ESMO 2023-10-22 15:05
Jacobio Pharma Announces 2023 Interim Results 2023-08-30 21:45
Jacobio Pharma Announces Breakthrough Therapy Designation from China CDE for KRAS G12C Inhibitor Glecirasib for the Treatment of Pancreatic Cancer 2023-08-07 20:03
Jacobio Pharma to Present Data of Glecirasib in Combination with JAB-3312 at the 2023 ESMO Conference 2023-07-21 10:19
Jacobio Receives CDE Approval for Glecirasib's Pancreatic Cancer Pivotal Study in China 2023-07-04 21:16
Jacobio Pharma Presents Clinical Results of Glecirasib in Colorectal Cancer 2023-06-29 16:31
Jacobio Pharma Announces 2022 Annual Results 2023-03-22 22:38
Jacobio announces clinical collaboration to evaluate CD73 monoclonal antibody JAB-BX102 in combination with KEYTRUDA® (pembrolizumab) for patients with cancer 2023-03-22 12:36
Jacobio Pharma to Present Data of Three Preclinical Studies at the 2023 AACR Annual Meeting 2023-03-15 10:45
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S 2023-01-08 14:17
Jacobio's KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE 2022-12-16 08:42
Jacobio's Preclinical Results of KRAS G12C Inhibitor in Combination with SHP2 Inhibitor Will be Presented at the ESMO Asia Congress 2022 2022-12-02 08:30
1 2